Sagimet Biosciences (NASDAQ: SGMT) net income
Sagimet Biosciences reported a net loss of $51.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $45.6m. Earnings per share were −$1.58.
Sagimet Biosciences's best year of the last 4 was fiscal 2023. It reported a loss in 4 of those 4 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$51.0m | — | — | −$1.58 |
| 2024 | −$45.6m | — | — | −$1.45 |
| 2023 | −$27.9m | — | −1,393.8% | −$2.66 |
| 2022 | −$30.5m | — | — | −$165.20 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Sagimet Biosciences net income compared with its sector
By net income for its latest fiscal year, Sagimet Biosciences ranks 257th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 255th | Opus Genetics | −$49.6m | −349.3% |
| 256th | Lexicon Pharmaceuticals | −$50.3m | −101.1% |
| 257th | Sagimet Biosciences | −$51.0m | — |
| 258th | Establishment Labs | −$51.1m | −24.2% |
| 259th | Evolus | −$51.6m | −17.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Sagimet Biosciences
- How much did Sagimet Biosciences earn in fiscal 2025?
- Sagimet Biosciences reported a net loss of $51.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $45.6m.
- What are the earnings per share of Sagimet Biosciences?
- They were −$1.58 in fiscal 2025, compared with −$1.45 in fiscal 2024.
- Where does Sagimet Biosciences rank in its sector by net income?
- It ranks 257th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Sagimet Biosciences come from?
- From the annual report (Form 10-K) that Sagimet Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Sagimet Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Sagimet Biosciences: the Sagimet Biosciences page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.